iCAD and CancerIQ Announce Partnership to Integrate AI-Enabled Technology With Best-in-Class Risk Assessment and Care Management Platform Offering A Comprehensive Breast Health Care Solution
20 November 2023 - 2:00PM
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in
innovative cancer-detection solutions, and CancerIQ, the precision
cancer prevention platform streamlining provider workflows and
activating high-risk patients, today announced a new partnership to
create a best-in-class breast health care solution. The partnership
will provide a seamless way to uniquely inform physicians and
patients of cancer risk (including lifetime, genetic, and
AI-detected near-term risk), identify breast cancer at earlier
stages, when treatments work best, and increase patient adherence
to their personalized care plans.
Together, these solutions will combine elements from iCAD’s
artificial intelligence-enabled ProFound Breast Health Suite with
CancerIQ’s software and services, giving users a 2.4x more accurate
prediction of breast cancer risk by combining AI-informed 1- or
2-year risk with lifetime risk, as well as a unique care management
and patient activation workflow solution proven to more than double
adherence to payer-supported supplemental screening
recommendations.
“This partnership will streamline how patients and physicians
use our collective health data to schedule preventative screenings
and manage breast health care in a way that will save lives,” said
Dana Brown, president and CEO of iCAD. “We look forward to a
long-term relationship with CancerIQ that will create meaningful,
actionable information in terms of proactive and personalized care
benefiting both medical providers and the patients they
serve.”
CancerIQ helps providers traverse the challenges of managing
cancer risk assessments to offer more personalized, evidence-based
care pathways that lead to early cancer detection and prevention.
Integrated with leading EHR workflows, CancerIQ’s lifetime risk
calculator offers Tyrer-Cuzick scores (7 and 8), Gail, and NCCN
guidelines. Coupled with iCAD’s Density and short-term AI risk from
the ProFound Suite, clinicians will have a clear picture of a
patient’s future breast cancer risk and if breast cancer is
detected today.
“CancerIQ is on a mission to bring the latest innovations to a
broader population of providers so they can stay ahead of cancer.
Pairing our platform with iCAD’s AI-enabled product suite helps
fulfill that mission and bring a more complete solution to the
market,” said Feyi Ayodele, co-founder and CEO of CancerIQ.
The partnership aims to combine CancerIQ’s lifetime risk score
and genetic risk data with iCAD’s ProFound Density assessment score
and ProFound Risk, the only AI-informed short-term cancer risk
assessment that offers the industry’s highest AUC for providing a
one-year future risk estimation based on a 2D or 3D screening
mammogram. The ProFound Risk platform has a proven track record of
predicting risk of breast cancer 2.4x more accurately in the next
year than traditional lifetime risk models1. iCAD’s ProFound
Density Assessment will also become available, using mammography
images to categorize breast density, leading to personalized
patient care plans with supplemental screenings and a custom
schedule.
“There’s incredible power in blending our respective solutions
to create a product that is unmatched in the market,” said Michelle
Strong, iCAD’s COO.
The partnership announcement coincides with iCAD’s appearance at
the Radiological Society of North America (RSNA) annual meeting in
Chicago as the company unveils new research using AI in breast
cancer risk detection and heart disease.
About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD)
is a global leader on a mission to create a world where
cancer can’t hide by providing clinically proven AI-powered
solutions that enable medical providers to accurately and
reliably detect cancer earlier and improve patient
outcomes. Headquartered in Nashua, N.H., iCAD’s
industry-leading ProFound Breast Health Suite provides
AI-powered mammography analysis for breast cancer detection,
density assessment and risk evaluation. The ProFound Breast
Health Suite is cleared by the U.S. Food & Drug
Administration (FDA) and has received CE mark and Health
Canada licensing. Used by thousands of providers serving
millions of patients, ProFound is available in over 50
countries. For more information, visit www.icadmed.com.
About CancerIQ CancerIQ is the only
cancer-focused precision health platform that empowers healthcare
providers to detect cancer earlier and prevent it altogether across
all patient populations. Integrated directly into real-time EHR
workflows, CancerIQ makes it easy to gather comprehensive patient
data, automatically map it to the latest evidence-based guidelines,
and expand access to personalized care plans, cutting-edge clinical
solutions, and genomic innovations. Learn more at www.canceriq.com,
follow CancerIQ on Twitter or LinkedIn.
Citations:
- Mikael Eriksson et al. A risk model for digital breast
tomosynthesis to predict breast cancer and guide clinical care.
Sci. Transl. Med. 14, eabn3971 (2022).
DOI: 10.1126/scitranslmed.abn3971.
Media Contacts:
iCAD Media inquiries: pr@icadmed.com Investor
Inquiries: ir@icadmed.com
CancerIQ Media inquiries:
marketing@canceriq.com Investor Inquiries: bd@canceriq.com
Icad (NASDAQ:ICAD)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Icad (NASDAQ:ICAD)
Historical Stock Chart
Von Mai 2023 bis Mai 2024